| 2026 | Design, synthesis and biological evaluation of symmetric thiadiazole carboxamide derivative as glutaminase inhibitor | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS |
| 2026 | Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
| LUNG CANCER |
| 2026 | Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
| NATURE MEDICINE |
| 2026 | First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study | JOURNAL OF THORACIC ONCOLOGY |
| 2026 | Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis | LUNG CANCER |
| 2026 | Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2026 | Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report | JOURNAL OF THORACIC ONCOLOGY |
| 2026 | A Response to the Letter to the Editor: "Comment on COCOON: Daily 4% Chlorhexidine for Nail Care-Rationale, Safety, and Evidence Gaps" | JOURNAL OF THORACIC ONCOLOGY |
| 2026 | Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer
| ESMO OPEN |
| 2026 | A Response to the Letter to the Editor: "Lazertinib Versus Osimertinib in EGFR-Mutant NSCLC: Efficacy, Toxicity, and Unaddressed Clinical Gaps | JOURNAL OF THORACIC ONCOLOGY |
| 2026 | Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis | CLINICAL LUNG CANCER |
| 2026 | MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer | LUNG CANCER |
| 2026 | Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
| JOURNAL OF CLINICAL ONCOLOGY |
| 2025 | Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301 | Clinical Lung Cancer |
| 2025 | Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29) | ESOPHAGUS |
| 2025 | A Response to the Letter to the Editor: "Comparable or Indeterminate? A Critical Appraisal of Efficacy Claims in the MARIPOSA Exploratory Analysis | JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study | ESMO OPEN |
| 2025 | Modeling the metastatic tumor microenvironment: a co-culture platform of lung cancer and blood vessel organoids for drug evaluation
| SCIENTIFIC REPORTS |
| 2025 | Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
| TARGETED ONCOLOGY |
| 2025 | A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC | JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18 | EUROPEAN JOURNAL OF CANCER |
| 2025 | Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups | JOURNAL OF THORACIC ONCOLOGY |
| 2025 | A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America
| FRONTIERS IN ONCOLOGY |
| 2025 | Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial
| CANCER RESEARCH AND TREATMENT |
| 2025 | BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/ expansion multicenter study | ESMO OPEN |
| 2025 | LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy | JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5
| JTO CLINICAL AND RESEARCH REPORTS |
| 2025 | Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study
| JTO CLINICAL AND RESEARCH REPORTS |
| 2025 | Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum
| CANCERS |
| 2025 | Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer
| ONCOLOGY AND THERAPY |
| 2025 | Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
| EUROPEAN JOURNAL OF CANCER |
| 2025 | Evolving roles of MET as a therapeutic target in NSCLC and beyond | NATURE REVIEWS CLINICAL ONCOLOGY |
| 2025 | What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer? | JTO Clinical and Research Reports |
| 2025 | Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
| NATURE COMMUNICATIONS |
| 2025 | D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial | NATURE MEDICINE |
| 2025 | Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas | CLINICAL CANCER RESEARCH |
| 2025 | Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2025 | Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
| ANNALS OF ONCOLOGY |
| 2025 | Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor | Results in Chemistry |
| 2025 | Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
| LUNG CANCER |
| 2025 | A Response to the Letter to the Editor: "POSEIDON's Missing Piece: Unanswered Questions on PFS Data in High-Risk Subgroups" | JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer
| FUTURE ONCOLOGY |
| 2025 | Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
http://orcid.org/0000-0002-5562-270X
(7401747804)
